© 2023 MJH Life Sciences and Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
© 2023 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
January 20, 2023
Favorable safety and efficacy data were seen with envafolimab, lenvatinib and transarterial chemoembolization in patients with unresectable hepatocellular carcinoma.
December 13, 2022
Ciltacabtagene autoleucel continues to show promise for the treatment of relapsed or refractory multiple myeloma.
December 12, 2022
Clinical benefit has been achieved with zanubrutinib treatment in patients B-cell malignancies who were intolerant to acalabrutinib.
December 09, 2022
In the phase 1b/2 DESTINY-Breast07 study, positive results were shown with trastuzumab deruxtecan, even without the addition of pertuzumab.